Company Profile

Albireo Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its product, Bylvay, is for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) ages three months or older and is authorized in Europe for the treatment of PFIC in patients ages six months or older. Its product candidate elobixibat is licensed for the treatment of chronic constipation and other functional diseases in Japan and other select markets in Asia. Its lead candidate for adult liver diseases, A3907, is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) where systemic bioavailability has been demonstrated in preclinical and clinical studies. Its preclinical candidate for adult viral and liver diseases includes A2342.

Employees

Sector

Biotechnology & Medical Research

More about the company

23-03-03	CAC40: in green, gains over 2% on a weekly basis
23-03-03	CAC40: PMI and ISM data point to 22nd week of gains

23-03-03	CAC40: in green, gains over 2% on a weekly basis
23-03-03	CAC40: PMI and ISM data point to 22nd week of gains
23-03-03	CAC40: 7350 in sight if rates continue to ease
23-03-03	CAC40: breaks through 7300 pts after Bostic's comments
23-03-03	Ipsen: acquisition of Albireo Pharma finalized
23-03-02	French Drugmaker Ipsen Concludes Albireo Pharma Takeover	MT
23-03-02	Albireo Pharma, Inc. Announces Board Changes	CI
23-03-02	Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from NASDAQ Composite Index	CI
23-03-02	Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P TMI Index	CI
23-03-02	Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P Global BMI Index	CI
23-02-28	Ipsen Biopharmaceuticals, Inc. completed the acquisition of Albireo Pharma, Inc. from a group of shareholders.	CI
23-02-22	Ipsen Extends Tender Offer for Albireo Pharma as It Awaits US Antitrust Clearance	MT
23-02-22	Ipsen: extension of the deadline for its tender offer for Albireo Pharma

23-01-11	Guggenheim Downgrades Albireo Pharma to Neutral From Buy	MT
23-01-11	Cowen Downgrades Albireo Pharma to Market Perform From Outperform, Adjusts Price Target to $48 From $68	MT
23-01-11	Jefferies Downgrades Albireo Pharma to Hold From Buy, Adjusts Price Target to $42 From $49	MT
23-01-10	Baird Adjusts Price Target on Albireo Pharma to $45 From $55, Maintains Outperform Rating	MT
23-01-10	HC Wainwright Downgrades Albireo Pharma to Neutral From Buy, Price Target is $42	MT

23-03-02	ALBIREO PHARMA, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
23-02-15	Albireo Pharma, Inc. - FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay in Alagille Syndrome	AQ
23-02-14	ALBIREO PHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
23-02-14	FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome	AQ
23-01-24	ALBIREO PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albireo Pharma, Inc. - ALBO	BU

23-03-03	CAC40 : en vert, s'arroge plus de 2% en données hebdomadaires
23-03-03	CAC40 : vers la 22ème semaine de progression après PMI et ISM
23-03-03	CAC40 : 7350 en ligne de mire si la détente des taux continue
23-03-03	CAC40 : franchit les 7300 pts après les propos de Bostic
23-03-03	Les valeurs à suivre aujourd'hui à la Bourse de Paris - Vendredi 3 mars 2023

Biodel Inc Stock Nasdaq

Stocks

US09064M1053

Biotechnology & Medical Research

Latest news: Biodel Inc

Analysts' recommendations: Biodel Inc

Press Releases: Biodel Inc

News in other languages: Biodel Inc

Managers and Directors: Biodel Inc

Bio Therapeutic Drugs

Company Profile

Manager	Title	Age	Since
Christelle Huguet CEO	Chief Executive Officer	59	2023-03-01
Abla Abrial TRE	Treasurer	-	-
Jennifer Benenson SEC	Corporate Secretary	-	2023-03-01

Director	Title	Age	Since
François-Maurice Garnier BRD	Director/Board Member	64	2023-03-01
Aymeric Le Chatelier BRD	Director/Board Member	57	2023-03-01
Alan Sokaler BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.41B
ARGENX SE	-1.50%	-1.92%	+23.95%	+77.52%	59.26B
LONZA GROUP AG	+1.32%	-0.32%	+4.61%	+34.93%	47.14B
IQVIA HOLDINGS INC.	-3.02%	-5.20%	+27.94%	+32.51%	42.91B
REVOLUTION MEDICINES, INC.	+0.31%	+3.02%	+348.95%	+643.82%	44.13B
BEONE MEDICINES AG	-1.96%	-0.33%	+7.04%	+99.46%	40.79B
CELLTRION, INC.	+3.32%	+3.49%	+10.10%	+51.23%	30.77B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.63%	+22.72%	29.31B
INSMED INCORPORATED	-4.86%	-10.66%	-26.27%	+330.06%	23.71B
Average	-0.55%	-0.52%	+52.81%	+154.05%	43.6B
Weighted average by Cap.	-0.01%	-0.32%	+57.98%	+145.71%

End-of-day quote Nasdaq
- ^USD	-